Haisco Pharma's HSK45030 receives IND application acceptance

Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) announced that its subsidiary, Xizang Haisco Pharmaceutical Co., Ltd., has received an "Acceptance Notice" from the National Medical Products Administration for its innovative drug, HSK45030 dispersible tablets. The drug, designed for the treatment of muscular dystrophy, is classified as a Class 1 chemical drug. Preclinical studies suggest HSK45030 effectively reduces muscle damage caused by excessive muscle contraction and exhibits excellent anti-myotonic effects in animal models, with good tolerability and a wide safety window. While the IND application has been accepted, Haisco Pharma cautions investors about the lengthy development cycle and inherent risks associated with innovative drug development. The company commits to fulfilling its information disclosure obligations regarding the project's future progress.